486 related articles for article (PubMed ID: 28163010)
21. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
Xu J; Zhang Y; Hu J; Ren Y; Wang H
Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
[No Abstract] [Full Text] [Related]
22. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
23. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
24. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.
Lyu X; Xin Y; Mi R; Ding J; Wang X; Hu J; Fan R; Wei X; Song Y; Zhao RY
PLoS One; 2014; 9(3):e92470. PubMed ID: 24667279
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
[TBL] [Abstract][Full Text] [Related]
27. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
Ahmed ZA; Shaikh MS; Moatter T
J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.
Mossallam GI; Abdel Hamid TM; Mahmoud HK
Hematology; 2013 Mar; 18(2):69-73. PubMed ID: 23394625
[TBL] [Abstract][Full Text] [Related]
30. [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].
Zhang R; Sun HQ; Li G; Bai FY; Yang Y; Jing Q; Shi YJ; Yang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):959-63. PubMed ID: 21867623
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
32. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
[TBL] [Abstract][Full Text] [Related]
33. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
[TBL] [Abstract][Full Text] [Related]
34. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
[TBL] [Abstract][Full Text] [Related]
35. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
36. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Miglino M; Colombo N; Pica G; Grasso R; Clavio M; Bergamaschi M; Ballerini F; Ghiso A; Ghiggi C; Mitscheunig L; Beltrami G; Cagnetta A; Vignolo L; Lucchetti MV; Aquino S; Pierri I; Sessarego M; Carella AM; Gobbi M
Leuk Lymphoma; 2011 Oct; 52(10):1961-9. PubMed ID: 21942328
[TBL] [Abstract][Full Text] [Related]
37. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
[TBL] [Abstract][Full Text] [Related]
38. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
39. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
40. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
